凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花集团:2012年第三季度报告

公告日期 2012-10-31
股票简称:梅花生物 股票代码:600873
梅花生物科技集团股份有限公司
           600873
    2012 年第三季度报告
    600873                            梅花生物科技集团股份有限公司 2012 年第三季度报告
                                 目       录§1 重要提示 .............................................................. 2§2 公司基本情况 .......................................................... 2§3 重要事项 .............................................................. 3§4 附录 .................................................................. 6
    600873                                        梅花生物科技集团股份有限公司 2012 年第三季度报告§1 重要提示1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。1.2 公司全体董事出席董事会会议。1.3 公司第三季度财务报告未经审计。1.4
    公司负责人姓名                                        孟庆山
    主管会计工作负责人姓名                                李勇刚
    会计机构负责人(会计主管人员)姓名                    陶忠公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠声明:保证本季度报告中财务报告的真实、完整。§2 公司基本情况2.1 主要会计数据及财务指标
                                                                                              币种:人民币
                                                                                         本报告期末比上年
                                                  本报告期末           上年度期末
                                                                                           度期末增减(%)
    总资产(元)                                   15,370,167,757.64 13,840,835,835.01                    11.05
    所有者权益(或股东权益)(元)                  5,269,305,220.22    5,144,277,853.53                   2.43
    归属于上市公司股东的每股净资产(元/股)                    1.95                  1.90                2.63
                                                        年初至报告期期末
                                                                                         比上年同期增减(%)
                                                            (1-9 月)
    经营活动产生的现金流量净额(元)                                      887,878,143.70                    67.35
    每股经营活动产生的现金流量净额(元/股)                                          0.33                 67.35
                                                   报告期          年初至报告期期末      本报告期比上年同
                                                 (7-9 月)           (1-9 月)           期增减(%)
    归属于上市公司股东的净利润(元)                  114,476,284.42      395,851,026.99                     5.55
    基本每股收益(元/股)                                      0.04                  0.15                  5.55
    扣除非经常性损益后的基本每股收益(元/股)                    0.04                  0.12                 25.48
    稀释每股收益(元/股)                                      0.04                  0.15                  5.55
    加权平均净资产收益率(%)                                  2.09                  7.41   减少 0.14 个百分点扣除非经常性损益后的加权平均净资产收益率
                                                                2.14             5.99    增加 0.22 个百分点(%)扣除非经常性损益项目和金额:
                                                                                    单位:元 币种:人民币
                                                                             年初至报告期期末金额
                               项目
                                                                                 (1-9 月)
    非流动资产处置损益                                                                         -2,085,300.74计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政
                                                                                             99,229,012.25策规定、按照一定标准定额或定量持续享受的政府补助除外除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、
    交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交                               259,558.84易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                                                          -607,182.40
    其他符合非经常性损益定义的损益项目                                                          -6,290,951.50
    所得税影响额                                                                               -14,670,066.59
                               合计                                                          75,835,069.862.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                                  单位:股
    600873                                           梅花生物科技集团股份有限公司 2012 年第三季度报告
    报告期末股东总数(户)                                                                                  71,080
                                  前十名无限售条件流通股股东持股情况
          股东名称(全称)           期末持有无限售条件流通股的数量                         种类
    胡继军                                                        369,394,122              人民币普通股
    香港鼎晖生物科技有限公司                                      335,625,120              人民币普通股
    新天域生化科技投资有限公司                                    261,106,616              人民币普通股
    李宝骏                                                         58,020,019              人民币普通股
    山东五洲投资集团有限公司                                       53,859,966              人民币普通股
    梁宇擘                                                         53,668,518              人民币普通股
    王加琪                                                         19,823,507              人民币普通股
    郭振群                                                         19,340,006              人民币普通股
    潘耀冬                                                         18,856,506              人民币普通股
    王友山                                                         18,131,256              人民币普通股§3 重要事项3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因√适用 □不适用1.资产负债表项目(单位:万元)
    项目                                     本报告期末         上年度期末           增减额               增减幅度%
    货币资金                                  103292.89          186286.86        -82993.97                  -44.55
    应收账款                                    41354.5           24509.97         16844.52                   68.73
    其他应收款                                  2617.69            5109.69            -2492                  -48.77
    在建工程                                 372,836.46         130,695.45        242141.01                  185.27
    工程物资                                   6,153.01          12,479.78         -6326.77                  -50.70
    应付票据                                  47,195.00          31,565.00            15630                   49.52
    应付账款                                 109,674.09          68,663.65         41010.43                   59.73
    应付利息                                  14,415.28           8,290.11          6125.17                   73.89
    应付债券                                 188,646.25          99,031.17         89615.09                   90.49
    其他非流动负债                             5,213.10           3,820.00           1393.1                   36.472.利润表项目(单位:万元)
    项目                          本报告期                  上年同期              增减额                  增减幅度%
    财务费用                     23,714.75                 15,709.39            8,005.37                      50.963.现金流量表项目(单位:万元)
                项目                         本报告期           上年同期            增减额             增减幅度%
    经营活动产生的现金流量净额                 88,787.81          53,055.95         35,731.86                 67.35
    筹资活动产生的现金流量净额                  7,126.63         144,992.56       -137,865.93                -95.08
    4.项目变动原因说明(1)货币资金比上年度期末下降 44.55%,主要原因是本报告期投资新疆项目和偿还借款及支付利息所致。(2)应收账款比上年度期末上升 68.73%,主要原因是本报告期产品销售收入增加且味精客户授信增加
    600873                                     梅花生物科技集团股份有限公司 2012 年第三季度报告所致。(3)其他应收款比上年度期末下降 48.77%,主要原因是本报告期收回通辽科尔沁工业园区管委会借款及收到出口退税款所致。(4)在建工程比上年度期末上升 185.27%,主要原因是新疆梅花氨基酸工程增加所致。(5)工程物资比上年度期末下降 50.7%,主要原因是新疆梅花氨基酸工程领用所致。(6)应付票据比上年度期末上升 49.52%,主要原因是票据尚未到期所致。(7)应付账款比上年度期末上升 59.73%,主要原因是应付新疆梅花氨基酸工程款以及五金设备货款增加所致。(8)应付利息比上年度期末上升 73.89%,主要原因是本期计提借款利息增加所致。(9)应付债券比上年度期末上升 90.49%,主要原因是本报告期发行中期票据 9 亿所致。(10)其他非流动负债比上年度期末上升 36.47%,主要原因是本报告期新疆梅花收到项目建设基础设施配套补贴所致。(11)财务费用比上年同期上升 50.96%,主要原因是本报告期利息支出增加所致。(12)经营活动产生的现金流量净额比上年同期上升 67.35%,主要原因是本报告期随营业收入增加收款增加所致。(13)筹资活动产生的现金流量净额比上年同期下降 95.08%,主要原因是本报告期减少借款和偿还借款及利息支出增加所致。3.2 重大事项进展情况及其影响和解决方案的分析说明√适用 □不适用
    1.2011 年 4 月 22 日公司召开六届五次董事会,并于 2011 年 5 月 20 日召开 2011 年第二次临时股东大会,审议通过了《关于公司 2011 年非公开发行股票方案的议案》等议案。
         公司拟向特定对象非公开发行的股票合计不超过 3.2 亿股,每股价格不低于 14.66 元,计划募集资金总额不超过 470,000 万元,扣除发行费用后募集资金净额预计不超过 450,000 万元,募集资金用于新疆项目建设。在非公开发行募集资金到位之前,公司将根据募集资金投资项目进度的实际情况以自筹资金先行投入,并在募集资金到位后按照相关法规规定的程序予以置换。截至本报告期末已投入资金 446,059.56 万元。
    由于国内资本市场环境有所变化,为保证本次非公开发行股票工作顺利进行,公司分别于 2012年 2 月 22 日和 2012 年 3 月 22 日召开六届十四次董事会和 2011 年度股东大会,审议通过《关于调整公司 2011 年非公开发行股票方案的议案》,对 2011 年非公开发行股票方案的发行数量、发行价格等相关内容进行调整,详见上海证券交易所公告。
    目前本次非公开发行股票事宜涉及到的环境保护核查已获得环境保护部的批准。公司已于 2012年 9 月 27 日收到中国证券监督管理委员会出具的书面核准文件。未来,公司将选择合适的时机发行。
    2.公司分别于 2012 年 7 月 13 日和 7 月 30 日召开六届十九次董事会和 2012 年第一次临时股东大会,审议通过《关于变更公司住所的议案》:考虑到公司业务长远发展的需要,将公司住所由原"西藏
    600873                                          梅花生物科技集团股份有限公司 2012 年第三季度报告自治区拉萨市北京西路 224 号,邮编 850001"变更为"西藏自治区拉萨经济技术开发区(金珠西路 189号),邮编 851400",公司办公地址不变。
      目前,公司住所变更涉及到的工商登记手续尚在办理之中。3.3 公司、股东及实际控制人承诺事项履行情况√适用 □不适用承
                                                                                     是否有
    诺      承诺                                                                                 是否及时
                   承诺方                           承诺内容                         履行期
    背      类型                                                                                 严格履行
                                                                                       限景
                               孟庆山及其一致行动人承诺:重组实施完毕后的三年归属
         盈利                  母公司净利润不低于北京天健兴业资产评估有限公司出
         预测   孟庆山及其一   具的编号为天兴评报字(2009)第 117 号《资产评估报告
                                                                                       是        是
         及补   致行动人       书》上的盈利预测数,即 2010 年归属母公司净利润
         偿                    67,311.14 万元,2011 年归属母公司净利润 61,890.37
                               万元,2012 年归属母公司净利润 58,847.22 万元。与重
    大                            孟庆山及其一致行动人承诺:通过重大资产重组取得的股
         股份   孟庆山及其一
    资                            份自登记至其账户之日起三十六个月内不上市交易或转        是        是
         限售   致行动人
    产                            让。重
    组                            在重组完成后,孟庆山先生及一致行动人将尽量避免与上
    相                            市公司的关联交易,若有不可避免的关联交易,孟庆山先
         解决
    关             孟庆山及其一   生及一致行动人与上市公司将依法签订协议,履行合法程
         关联                                                                          是        是
    的             致行动人       序,并将按照有关法律、法规、《公司章程》等有关规定
         交易
    承                            履行信息披露义务和办理有关报批事宜。保证不通过关联
    诺                            交易损害上市公司及其他股东的合法权益。
                               在孟庆山先生及一致行动人作为上市公司控股股东或实
         解决                  际控制人之期限内,将采取有效措施,并促使孟庆山先生
                孟庆山及其一
         同业                  或孟庆山先生及一致行动人下属控股子公司采取有效措        是        是
                致行动人
         竞争                  施,不会从事或参与任何可能对上市公司或其控股子公司
                               目前主要从事的业务构成竞争的业务。3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
      □适用 √不适用3.5 报告期内现金分红政策的执行情况
      公司 2012 年半年度利润分配方案(预案)分别经六届二十次董事会和 2012 年第二次临时股东大会审议通过:以总股本 2,708,236,603 股为基数,向全体股东每 10 股分配现金股利 1.00 元(含税),预计分配利润 270,823,660.30 元。公司将严格按照中国证监会、上海证券交易所和《公司章程》的规定实施上述现金分红事项。
                                                                         梅花生物科技集团股份有限公司
                                                                                       法定代表人:孟庆山
                                                                                     __________________
                                                                                       2012 年 10 月 30 日
    600873                                  梅花生物科技集团股份有限公司 2012 年第三季度报告§4 附录
                                     合并资产负债表
                                    2012 年 9 月 30 日编制单位: 梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                          项目                     期末余额                  年初余额流动资产:
    货币资金                                      1,032,928,913.82         1,862,868,600.12
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                                         53,097,739.00            54,719,220.00
    应收账款                                        413,544,961.62           245,099,721.97
    预付款项                                      2,029,357,870.93         1,826,380,874.46
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                       26,176,948.87            51,096,929.99
    买入返售金融资产
    存货                                          1,204,476,999.86         1,238,421,023.13
    一年内到期的非流动资产
    其他流动资产
         流动资产合计                              4,759,583,434.10         5,278,586,369.67非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                    150,461,428.10           148,956,018.85
    投资性房地产
    固定资产                                      5,844,917,481.18         6,142,508,095.94
    在建工程                                      3,728,364,580.95         1,306,954,507.51
    工程物资                                         61,530,103.73           124,797,797.68
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                        808,119,951.25           813,379,442.76
    开发支出
    商誉                                             11,788,911.79            18,079,863.29
    长期待摊费用
    递延所得税资产                                    5,401,866.54             7,573,739.31
    其他非流动资产
         非流动资产合计                           10,610,584,323.54         8,562,249,465.34
             资产总计                             15,370,167,757.64        13,840,835,835.01
    600873                                    梅花生物科技集团股份有限公司 2012 年第三季度报告流动负债:
    短期借款                                        4,192,130,345.00          4,260,003,491.63
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                          471,950,000.00            315,650,000.00
    应付账款                                        1,096,740,868.78            686,636,541.98
    预收款项                                          174,766,376.26            196,190,935.80
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                       29,944,683.02             38,805,490.11
    应交税费                                         -492,771,408.57           -434,752,747.34
    应付利息                                          144,152,807.39             82,901,085.19
    应付股利                                          270,823,660.30
    其他应付款                                        209,531,680.09            202,611,521.71
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
         流动负债合计                                6,097,269,012.27          5,348,046,319.08非流动负债:
    长期借款                                        2,065,000,000.00          2,320,000,000.00
    应付债券                                        1,886,462,537.40            990,311,662.40
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                                     52,130,987.75             38,200,000.00
         非流动负债合计                              4,003,593,525.15          3,348,511,662.40
           负债合计                                 10,100,862,537.42          8,696,557,981.48所有者权益(或股东权益):
    实收资本(或股本)                              2,708,236,603.00          2,708,236,603.00
    资本公积                                          187,528,409.88            187,528,409.88
    减:库存股
    专项储备
    盈余公积                                          128,335,925.96            128,335,925.96
    一般风险准备
    未分配利润                                      2,245,204,281.38          2,120,176,914.69
    外币报表折算差额
    归属于母公司所有者权益合计                      5,269,305,220.22          5,144,277,853.53
    少数股东权益
             所有者权益合计                          5,269,305,220.22          5,144,277,853.53
           负债和所有者权益总计                     15,370,167,757.64         13,840,835,835.01
    公司法定代表人: 孟庆山            主管会计工作负责人:李勇刚             会计机构负责人:陶忠
    600873                                  梅花生物科技集团股份有限公司 2012 年第三季度报告
                                    母公司资产负债表
                                    2012 年 9 月 30 日编制单位: 梅花生物科技集团股份有限公司
                                                   单位:元 币种:人民币 审计类型:未经审计
                          项目                     期末余额                  年初余额流动资产:
    货币资金                                         52,218,047.66           992,270,244.25
    交易性金融资产
    应收票据                                                                  22,883,450.00
    应收账款                                         95,134,016.87           139,432,742.38
    预付款项                                         15,564,781.12           224,799,167.86
    应收利息
    应收股利                                                                 400,000,000.00
    其他应收款                                    6,120,992,419.03         3,307,900,198.45
    存货                                             44,859,111.59            86,526,972.03
    一年内到期的非流动资产
    其他流动资产
         流动资产合计                              6,328,768,376.27         5,173,812,774.97非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                  2,933,461,428.10         2,638,956,018.85
    投资性房地产
    固定资产                                        817,903,315.57         1,038,225,491.60
    在建工程                                         36,741,330.94            67,505,341.08
    工程物资                                                                       2,271.72
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                         97,940,501.30           100,203,803.67
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                                        8,774.68                 8,774.68
    其他非流动资产
         非流动资产合计                            3,886,055,350.59         3,844,901,701.60
           资产总计                               10,214,823,726.86         9,018,714,476.57流动负债:
    短期借款                                      2,280,500,000.00         2,456,953,552.66
    交易性金融负债
    应付票据
    应付账款                                         43,253,191.56           289,486,477.08
    预收款项                                          1,543,285.93            17,703,208.59
    应付职工薪酬                                      1,897,225.00             7,713,444.31
    600873                                          梅花生物科技集团股份有限公司 2012 年第三季度报告
    应交税费                                                 -3,320,996.27             -4,944,280.85
    应付利息                                                142,283,672.25             79,830,833.32
    应付股利                                                270,823,660.30
    其他应付款                                              818,275,923.55             38,437,903.60
    一年内到期的非流动负债
    其他流动负债
         流动负债合计                                      3,555,255,962.32          2,885,181,138.71非流动负债:
    长期借款                                              1,500,000,000.00          1,500,000,000.00
    应付债券                                              1,886,462,537.40            990,311,662.40
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
         非流动负债合计                                    3,386,462,537.40          2,490,311,662.40
           负债合计                                        6,941,718,499.72          5,375,492,801.11所有者权益(或股东权益):
    实收资本(或股本)                                    2,708,236,603.00          2,708,236,603.00
    资本公积                                                155,744,114.24            155,744,114.24
    减:库存股
    专项储备
    盈余公积                                                128,335,925.96            128,335,925.96
    一般风险准备
    未分配利润                                              280,788,583.94            650,905,032.26
    所有者权益(或股东权益)合计                              3,273,105,227.14          3,643,221,675.46
           负债和所有者权益(或股东权益)总计             10,214,823,726.86          9,018,714,476.57
    公司法定代表人: 孟庆山                  主管会计工作负责人:李勇刚             会计机构负责人:陶忠
    600873                                            梅花生物科技集团股份有限公司 2012 年第三季度报告
                                                  合并利润表编制单位: 梅花生物科技集团股份有限公司
                                                            单位:元 币种:人民币 审计类型:未经审计
                                                                                             上年年初至报告
                                      本期金额           上期金额        年初至报告期期
             项目                                                                           期期末金额(1-9
                                    (7-9 月)        (7-9 月)       末金额(1-9 月)
                                                                                                  月)
    一、营业总收入                   1,613,919,418.05   1,674,932,620.33    5,401,494,334.84   4,614,247,610.74
    其中:营业收入                   1,613,919,418.05   1,674,932,620.33    5,401,494,334.84   4,614,247,610.74
    利息收入已赚保费手续费及佣金收入
    二、营业总成本                   1,452,578,983.45   1,554,987,076.19    4,969,136,885.49   4,112,981,780.21
    其中:营业成本                   1,238,998,971.68   1,313,706,185.58    4,224,539,777.17   3,458,493,970.94利息支出手续费及佣金支出
    退保金
    赔付支出净额
    提取保险合同准备金净额保单红利支出分保费用
    营业税金及附加                       5,460,851.63       7,447,108.24       13,485,579.09      19,984,615.18
    销售费用                            67,324,115.08      81,209,551.04      237,391,254.45     231,167,518.69
    管理费用                            72,820,030.77      86,586,335.42      254,730,918.62     237,795,167.11
    财务费用                            67,975,014.29      66,037,895.91      237,147,529.82     157,093,858.52
    资产减值损失                                                                1,841,826.34       8,446,649.77加:公允价值变动收益(损失以“-”号填列)
    投资收益(损失以“-”号填列)      -5,688,156.80          187,021.57      -4,525,983.41         403,460.85
    其中:对联营企业和合营企业
                                        602,794.70         -226,652.59       1,505,409.25        -298,624.26的投资收益
    汇兑收益(损失以“-”号填列)三、营业利润(亏损以“-”号
                                    155,652,277.80     120,132,565.71      427,831,465.94     501,669,291.38填列)
       加:营业外收入                 5,099,945.11      18,721,471.60      100,637,807.48     129,227,019.88
       减:营业外支出                 1,200,385.48       1,049,578.55        4,101,278.37       2,475,027.60
       其中:非流动资产处置损失         174,091.40         548,762.52        2,834,116.19       1,228,777.54四、利润总额(亏损总额以“-”
                                    159,551,837.43     137,804,458.76      524,367,995.05     628,421,283.66号填列)
       减:所得税费用                45,075,553.01      29,350,337.97      128,516,968.06     127,389,344.40五、净利润(净亏损以“-”号
                                    114,476,284.42     108,454,120.79      395,851,026.99     501,031,939.26填列)
    归属于母公司所有者的净利润       114,476,284.42     108,454,120.79      395,851,026.99     501,031,939.26
       少数股东损益六、每股收益:
       (一)基本每股收益                    0.04                 0.04               0.15               0.19
       (二)稀释每股收益                    0.04                 0.04               0.15               0.19七、其他综合收益
    八、综合收益总额                   114,476,284.42     108,454,120.79      395,851,026.99     501,031,939.26归属于母公司所有者的综合收
                                    114,476,284.42     108,454,120.79      395,851,026.99     501,031,939.26益总额
    归属于少数股东的综合收益总额
    公司法定代表人: 孟庆山                 主管会计工作负责人:李勇刚                会计机构负责人:陶忠
    600873                                              梅花生物科技集团股份有限公司 2012 年第三季度报告
                                      母公司利润表编制单位: 梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                                                                                                     上年年初至报告
                                             本期金额              上期金额       年初至报告期期
                  项目                                                                               期期末金额(1-9
                                            (7-9 月)           (7-9 月)     末金额(1-9 月)
                                                                                                          月)
    一、营业收入                              91,528,908.10         358,895,384.03   437,339,313.57     1,326,196,756.03
    减:营业成本                          102,910,698.25        355,306,304.61   461,767,260.32     1,267,851,018.11
            营业税金及附加                    597,141.37             185,218.59     1,323,951.99         2,607,997.71
            销售费用                           62,763.60             929,866.91       286,942.53         4,403,598.86
            管理费用                       22,544,063.33          33,099,385.26    79,027,504.07       102,822,145.45
            财务费用                       19,870,283.09          35,816,179.46    88,567,462.99        81,094,786.41
            资产减值损失                                                   0.00       321,669.31        -4,989,023.80
    加:公允价值变动收益(损失以
                                                                           0.00“-”号填列)
         投资收益(损失以“-”号填列)    94,900,888.52            -226,652.59    95,812,194.73          -123,172.88
         其中:对联营企业和合营企业的
                                              602,794.70            -226,652.59     1,505,409.25          -297,885.18投资收益
    二、营业利润(亏损以“-”号填列)        40,444,846.98         -66,668,223.39   -98,143,282.91      -127,716,939.59
    加:营业外收入                         1,290,000.00           3,000,165.76     1,657,435.51         8,242,984.47
    减:营业外支出                           167,941.69           1,048,408.36     1,106,539.97         2,264,233.46
          其中:非流动资产处置损失             27,679.95             548,407.75       846,948.23         1,019,798.84三、利润总额(亏损总额以“-”号
                                           41,566,905.29         -64,716,465.99   -97,592,387.37      -121,738,188.58填列)
    减:所得税费用                             9,952.09            -983,972.32     1,700,400.65         4,129,697.21
    四、净利润(净亏损以“-”号填列)        41,556,953.20         -63,732,493.67   -99,292,788.02      -125,867,885.79五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额                          41,556,953.20         -63,732,493.67   -99,292,788.02      -125,867,885.79
    公司法定代表人: 孟庆山                    主管会计工作负责人:李勇刚                  会计机构负责人:陶忠
    600873                                        梅花生物科技集团股份有限公司 2012 年第三季度报告
                                    合并现金流量表
                                      2012 年 1—9 月编制单位: 梅花生物科技集团股份有限公司
                                                  单位:元 币种:人民币 审计类型:未经审计
                                                         年初至报告期期末金额    上年年初至报告期期末金
                       项目
                                                               (1-9 月)              额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                             5,346,311,887.86         4,796,084,956.04
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                              40,230,361.86             9,982,532.51
    收到其他与经营活动有关的现金                               128,521,376.38           134,664,096.02
        经营活动现金流入小计                                  5,515,063,626.10         4,940,731,584.57
    购买商品、接受劳务支付的现金                             3,562,598,355.86         3,368,136,363.80
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                             326,208,067.67           274,199,974.89
    支付的各项税费                                             422,642,603.68           442,766,916.82
    支付其他与经营活动有关的现金                               315,736,455.19           325,068,799.12
        经营活动现金流出小计                                  4,627,185,482.40         4,410,172,054.63
          经营活动产生的现金流量净额                            887,878,143.70           530,559,529.94二、投资活动产生的现金流量:
    收回投资收到的现金                                                                    1,200,000.00
    取得投资收益收到的现金                                         259,558.84               702,085.11
    处置固定资产、无形资产和其他长期资产收回的现
                                                                  2,963,804.53                44,851.00金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
        投资活动现金流入小计                                      3,223,363.37             1,946,936.11
    购建固定资产、无形资产和其他长期资产支付的现
                                                              1,980,689,625.98         2,050,522,466.62金
    投资支付的现金                                                                       54,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
        投资活动现金流出小计                                  1,980,689,625.98         2,104,522,466.62
          投资活动产生的现金流量净额                         -1,977,466,262.61        -2,102,575,530.51三、筹资活动产生的现金流量:
    吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                                       3,845,936,134.68         3,676,325,678.89
    发行债券收到的现金
    收到其他与筹资活动有关的现金                                                        130,000,000.00
        筹资活动现金流入小计                                  3,845,936,134.68         3,806,325,678.89
    偿还债务支付的现金                                       3,266,225,776.10         1,593,066,104.99
    分配股利、利润或偿付利息支付的现金                         320,156,371.52           627,353,843.26
    600873                                        梅花生物科技集团股份有限公司 2012 年第三季度报告
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                               188,287,672.67            135,980,152.48
       筹资活动现金流出小计                                   3,774,669,820.29          2,356,400,100.73
         筹资活动产生的现金流量净额                              71,266,314.39          1,449,925,578.16
    四、汇率变动对现金及现金等价物的影响                             2,804,299.22             -2,451,044.05
    五、现金及现金等价物净增加额                                -1,015,517,505.30           -124,541,466.46
    加:期初现金及现金等价物余额                             1,652,684,850.59          1,005,526,344.64
    六、期末现金及现金等价物余额                                   637,167,345.29            880,984,878.18
    公司法定代表人: 孟庆山            主管会计工作负责人:李勇刚                 会计机构负责人:陶忠
                                    母公司现金流量表
                                      2012 年 1—9 月编制单位: 梅花生物科技集团股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
                                                         年初至报告期期末金额     上年年初至报告期期末金
                       项目
                                                               (1-9 月)               额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                               472,093,911.88          1,405,682,573.69
    收到的税费返还                                                 203,016.88              9,982,532.51
    收到其他与经营活动有关的现金                             4,368,845,022.58          1,189,271,169.79
        经营活动现金流入小计                                  4,841,141,951.34          2,604,936,275.99
    购买商品、接受劳务支付的现金                               422,309,024.78          1,776,978,983.89
    支付给职工以及为职工支付的现金                              56,166,796.35             85,174,876.32
    支付的各项税费                                              22,896,883.83             58,644,329.98
    支付其他与经营活动有关的现金                             4,303,759,801.90          1,459,565,297.27
        经营活动现金流出小计                                  4,805,132,506.86          3,380,363,487.46
          经营活动产生的现金流量净额                             36,009,444.48           -775,427,211.47二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                     400,008,691.66            600,174,712.30
    处置固定资产、无形资产和其他长期资产收回的现
                                                                 36,044,216.36                    400.00金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
        投资活动现金流入小计                                    436,052,908.02            600,175,112.30
    购建固定资产、无形资产和其他长期资产支付的现
                                                                 14,081,155.59             58,180,011.59金
    投资支付的现金                                             124,207,837.62            384,000,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
        投资活动现金流出小计                                    138,288,993.21            442,180,011.59
          投资活动产生的现金流量净额                            297,763,914.81            157,995,100.71三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                       2,450,500,000.00          2,560,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                             3,112,906,255.25            478,633,616.26
        筹资活动现金流入小计                                  5,563,406,255.25          3,038,633,616.26
    偿还债务支付的现金                                       1,690,000,000.00            460,000,000.00
    分配股利、利润或偿付利息支付的现金                         206,625,556.48            566,600,565.09
    支付其他与筹资活动有关的现金                             4,901,700,000.00          1,776,006,849.23
        筹资活动现金流出小计                                  6,798,325,556.48          2,802,607,414.32
          筹资活动产生的现金流量净额                         -1,234,919,301.23            236,026,201.94
    四、汇率变动对现金及现金等价物的影响                                                      -1,056,682.64
    五、现金及现金等价物净增加额                                  -901,145,941.94           -382,462,591.46
    加:期初现金及现金等价物余额                               953,363,989.00            521,540,434.41
    六、期末现金及现金等价物余额                                    52,218,047.06            139,077,842.95
    公司法定代表人: 孟庆山            主管会计工作负责人:李勇刚                      会计机构负责人:陶忠
数据加载中...
prevnext
手机查看股票